Clinical Trial to Evaluate the Efficacy and Safety of Co-administration of JW0108+C2407 in Patients With Dyslipidemia

JW Pharmaceutical

Status and phase: Completed; Phase 3

Conditions: Dyslipidemia

Treatments: Drug: JW0108 + C2407; Drug: JW0108 + C2407 placebo

Study type: Interventional

Funder types: Industry

Identifiers

NCT06955104

JW24302

Details and patient eligibility

About

A Multi-center, Randomized, Double-blind, Parallel, Phase Ⅲ Clinical Trial to Evaluate the Efficacy and Safety of Co-administration of JW0108+C2407 in Patients with Dyslipidemia

Full description

To evaluate the efficacy and safety of JW0108+C2407 in dyslipidemia patients

Enrollment: 145 patients

Sex: All

Ages: 19+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Age of 19 years old at the time of written informed consent
• Patients with dyslipidemia

Exclusion criteria

• Secondary dyslipidemia
• Patient who does not meet the specified TG, LDL-C level

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind

---

145 participants in 2 patient groups

Experimental Group: JW0108 + C2407

Experimental group

Description:

For 8weeks QD(Quaque Die)

Treatment:

Drug: JW0108 + C2407

Control Group: JW0108 + C2407 placebo

Active Comparator group

Description:

For 8weeks QD(Quaque Die)

Treatment:

Drug: JW0108 + C2407 placebo